391 related articles for article (PubMed ID: 35844552)
1. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.
Golay J; Andrea AE; Cattaneo I
Front Immunol; 2022; 13():929895. PubMed ID: 35844552
[TBL] [Abstract][Full Text] [Related]
2. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
3. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
4. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
[TBL] [Abstract][Full Text] [Related]
5. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
Falconer DJ; Subedi GP; Marcella AM; Barb AW
ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
[TBL] [Abstract][Full Text] [Related]
6. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.
Kapur R; Kustiawan I; Vestrheim A; Koeleman CA; Visser R; Einarsdottir HK; Porcelijn L; Jackson D; Kumpel B; Deelder AM; Blank D; Skogen B; Killie MK; Michaelsen TE; de Haas M; Rispens T; van der Schoot CE; Wuhrer M; Vidarsson G
Blood; 2014 Jan; 123(4):471-80. PubMed ID: 24243971
[TBL] [Abstract][Full Text] [Related]
7. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
[TBL] [Abstract][Full Text] [Related]
8. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Peipp M; Lammerts van Bueren JJ; Schneider-Merck T; Bleeker WW; Dechant M; Beyer T; Repp R; van Berkel PH; Vink T; van de Winkel JG; Parren PW; Valerius T
Blood; 2008 Sep; 112(6):2390-9. PubMed ID: 18566325
[TBL] [Abstract][Full Text] [Related]
9. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
10. An atomistic perspective on antibody-dependent cellular cytotoxicity quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics.
Harbison A; Fadda E
Glycobiology; 2020 May; 30(6):407-414. PubMed ID: 31829411
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
12. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
14. Generation of FX
Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
[TBL] [Abstract][Full Text] [Related]
15. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
[TBL] [Abstract][Full Text] [Related]
16. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.
Bruggeman CW; Dekkers G; Bentlage AEH; Treffers LW; Nagelkerke SQ; Lissenberg-Thunnissen S; Koeleman CAM; Wuhrer M; van den Berg TK; Rispens T; Vidarsson G; Kuijpers TW
J Immunol; 2017 Jul; 199(1):204-211. PubMed ID: 28566370
[TBL] [Abstract][Full Text] [Related]
18. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity.
Li C; Chong G; Zong G; Knorr DA; Bournazos S; Aytenfisu AH; Henry GK; Ravetch JV; MacKerell AD; Wang LX
J Am Chem Soc; 2021 May; 143(20):7828-7838. PubMed ID: 33977722
[TBL] [Abstract][Full Text] [Related]
19. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity.
Sun Y; Izadi S; Callahan M; Deperalta G; Wecksler AT
J Biol Chem; 2021 Jul; 297(1):100826. PubMed ID: 34044019
[TBL] [Abstract][Full Text] [Related]
20. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
